Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome
Authors
Keywords
Squamous cell carcinomas, Somatic mutation, Mutation detection, Histology, Carcinomas, Cervical cancer, Lymph nodes, Metastasis
Journal
PLoS One
Volume 10, Issue 7, Pages e0133670
Publisher
Public Library of Science (PLoS)
Online
2015-07-22
DOI
10.1371/journal.pone.0133670
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy Cetuximab in Cervical Cancer Patients
- (2015) A. de la Rochefordiere et al. CLINICAL CANCER RESEARCH
- Prognosis of Adenosquamous Carcinoma Compared With Adenocarcinoma in Uterine Cervical Cancer
- (2014) Jung-Yun Lee et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Designing a High-Throughput Somatic Mutation Profiling Panel Specifically for Gynaecological Cancers
- (2014) Vivian M. Spaans et al. PLoS One
- Oncogenic mutations in cervical cancer
- (2013) Alexi A. Wright et al. CANCER
- KRASMutation: Should We Test for It, and Does It Matter?
- (2013) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Landscape of genomic alterations in cervical carcinomas
- (2013) Akinyemi I. Ojesina et al. NATURE
- Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
- (2013) Gunther Zimmermann et al. NATURE
- Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
- (2012) Libero Santarpia et al. BREAST CANCER RESEARCH AND TREATMENT
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- Wnt/β-Catenin Signaling and Disease
- (2012) Hans Clevers et al. CELL
- Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
- (2012) Andrey Voronkov et al. CURRENT PHARMACEUTICAL DESIGN
- Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis
- (2012) Ronald van Eijk et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K–AKT, Wnt/β-catenin and P53 pathway activation
- (2012) Remi A. Nout et al. GYNECOLOGIC ONCOLOGY
- Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm?
- (2012) Peter G. Rose GYNECOLOGIC ONCOLOGY
- Prognostic significance of adenocarcinoma histology in women with cervical cancer
- (2012) Vijaya Galic et al. GYNECOLOGIC ONCOLOGY
- Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: A systematic review
- (2012) Maria Lina Tornesello et al. GYNECOLOGIC ONCOLOGY
- PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
- (2012) John B. McIntyre et al. GYNECOLOGIC ONCOLOGY
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma
- (2012) K. Dutton-Regester et al. MOLECULAR CANCER THERAPEUTICS
- Worldwide burden of cervical cancer in 2008
- (2011) M. Arbyn et al. ANNALS OF ONCOLOGY
- PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors
- (2011) Bożena Konopka et al. HUMAN PATHOLOGY
- PI3K: A potential therapeutic target for cancer
- (2011) Yingwei Chen et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
- (2011) Mohammad H Forouzanfar et al. LANCET
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
- (2011) Filip Janku et al. PLoS One
- Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
- (2011) Shin Ogita et al. Targeted Oncology
- A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes
- (2010) Debora Fumagalli et al. BMC CANCER
- Automated Extraction of DNA and RNA from a Single Formalin-Fixed Paraffin-Embedded Tissue Section for Analysis of Both Single-Nucleotide Polymorphisms and mRNA Expression
- (2010) G. Hennig et al. CLINICAL CHEMISTRY
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Adenocarcinoma: A unique cervical cancer
- (2009) Lilian T. Gien et al. GYNECOLOGIC ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
- (2009) Laura E. MacConaill et al. PLoS One
- PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences
- (2008) Takahito Miyake et al. CANCER LETTERS
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started